161 related articles for article (PubMed ID: 1999706)
1. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
Marsh JC; Bertino JR; Katz KH; Davis CA; Durivage HJ; Rome LS; Richards F; Capizzi RL; Farber LR; Pasquale DN
J Clin Oncol; 1991 Mar; 9(3):371-80. PubMed ID: 1999706
[TBL] [Abstract][Full Text] [Related]
2. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
5. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
6. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Abad A; Garcia P; Gravalos C; Tusquets I; Font A; Perez G; Cortés-Funes H; Fabregat X; Barnadas A; Rosell R
Cancer; 1995 Mar; 75(6):1238-44. PubMed ID: 7882275
[TBL] [Abstract][Full Text] [Related]
7. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
[TBL] [Abstract][Full Text] [Related]
8. Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
Stabuc B; Markovic A; Plesnicar A; Cizej TE
Neoplasma; 2000; 47(4):248-52. PubMed ID: 11043831
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
[TBL] [Abstract][Full Text] [Related]
10. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM; Hatfield AK; Kahn M; Sargent DJ; Knost JA; O'Connell MJ; Krook JE; Maillard JA; Wiesenfeld M; Schaefer PL; Tirona MT; Moertel CG
J Clin Oncol; 1997 Nov; 15(11):3320-9. PubMed ID: 9363861
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
12. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
Nordic Gastrointestinal Tumor Adjuvant Therapy Group
J Clin Oncol; 1989 Oct; 7(10):1437-46. PubMed ID: 2674332
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
[TBL] [Abstract][Full Text] [Related]
14. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Cascinu S; Silva RR; Labianca R; Barni S; Mattioli R; Martignoni G; Frontini L; Gasparini G; Catalano V; Baldelli AM; Giuliodori L; Agostinelli R; Catalano G
Ann Oncol; 1999 Aug; 10(8):985-7. PubMed ID: 10509163
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
20. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
Blijham G; Wagener T; Wils J; de Greve J; Buset M; Bleiberg H; Lacave A; Dalmark M; Selleslag J; Collette L; Sahmoud T
J Clin Oncol; 1996 Aug; 14(8):2266-73. PubMed ID: 8708716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
